Sign Up
Stories
BioInvent's Collaboration for Lymphoma Treatment
Share
ADC Therapeutics Reports Financial Progr...
AI-Powered Cancer Drug Trials
Aadi Bioscience Validates FYARRO® for PE...
AB-2100 Phase 1/2 Trial Initiated
ADC Therapeutics Webcast Announced
Affini-T Therapeutics at J.P. Morgan Hea...
Overview
API
BioInvent International AB partners with AstraZeneca for a clinical study to evaluate BI-1206 in combination with rituximab and Calquence for non-Hodgkin's lymphoma, aiming to develop a new treatment option.
Ask a question
How could this collaboration influence the competitive landscape in the oncology drug market?
How might the success of this collaboration impact the pharmaceutical industry's approach to cancer treatment?
What challenges might BioInvent and AstraZeneca face in the development of this potential new treatment option?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage